Canenguez Benitez · Cureus 2022 · narrative review · n=27 studies

Advantages and Disadvantages of Using St. John's Wort as a Treatment for Depression.

Cited 22 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Narrative review without formal systematic review methodology or meta-analysis

PubMed 36299970 · doi:10.7759/cureus.29468 · record verified 2026-08-29

What was done

The authors searched PubMed, JAMA network, Springer Link, Elsevier, Google Scholar, and Scientific Progress for literature published between 2011 and August 2021 on St. John's wort (Hypericum perforatum) for depression and antidepressant interactions. After removing irrelevant and non-English articles, 27 papers were included in a qualitative narrative review.

What was found

The abstract reports no numerical data, effect sizes, or confidence intervals. St. John's wort was described as superior to placebo in mild and moderate depression, comparable in efficacy to tricyclic antidepressants, and comparable to or more effective than SSRIs such as fluoxetine. It was also reported to reduce postmenopausal depression. While better tolerated with fewer adverse effects than standard antidepressants, it carries risks of CYP450-mediated drug interactions and potentially fatal serotonin syndrome when combined with other serotonergic medications.

Why it matters

This review highlights that while St. John's wort has clinical efficacy comparable to standard antidepressants for mild-to-moderate depression, its severe pharmacokinetic interactions require careful clinical oversight.

Limits

The abstract provides no quantitative effect estimates, confidence intervals, or total participant sample size. It omits formal risk-of-bias evaluation, details on extract standardization or dosing, and excluded non-English studies.

Cited by